Hepion Pharmaceuticals (HEPA) Announces Passing of Key Safety Milestone in Phase 2b ‘ASCEND-NASH’ Trial...
Completion of Enrollment Remains on Track for Q1, 2024
"While we recently had fireworks, we could be looking at...
Hepion (HEPA) Back in the Spotlight, Gains 230% in May.
Hepion (HEPA) Phase 2 ‘ALTITUDE-NASH’ Trial Achieves Primary and Secondary Endpoints, Including Improvement in Liver Function and...
And We Have a $26.4 Billion Winning Trifecta!
THREE PREVIOUS WINNERS*
Immunomedics (IMMU) $3 to $87 up 2,800%, a gain of $20.7 billion. Acquired...
Revive Therapeutics (RVVTF) Enters the Danger Zone.
What Danger You Ask?
Danger #1, the FDA doesn't like the data, and you own the stock.
Report on Citius Pharma (CTXR): North Shore Research Issues a $10 Price Target, a...
We're Up 181% on Citius Pharma (CTXR), Despite its Being Well Below it's Recent High of $4.30. We Now Have Two $10...
Citius Pharmaceuticals Reports Topline Data from the Pivotal Phase 3 Study of Cancer Immunotherapy.
Citius Pharmaceuticals Reports Topline Data from the Pivotal Phase 3 Study of Cancer Immunotherapy I/ONTAK (E7777) for the Treatment of Persistent or...
Citius Pharma (CTXR) Flexes Muscle in Business Update. Remains Our Top Idea.
Added to Watch List November 2019 @$0.55.
Named Our Top Idea in 2020 @$1.02.Remains Our Top Idea in 2021...
Hapbee (HAPB) Expands Leadership Team to Support Aggressive Growth Strategy
VANCOUVER, BC, Aug. 6, 2021 /CNW/ - Hapbee Technologies, Inc. (TSXV: HAPB) (OTCQB: HAPBF) (FSE: HA1) ("Hapbee" or the "Company"), the leading wearable, wellness technology company has...
Citius Pharma (CTXR) $2.15. Price Target of $8.00 Maintained, Post Safety and Efficacy Review.
Investment Banker Buy Rating Maintained: DSMB Gives the Thumbs Up – Data in Early 2022.
CITIUS NEWS ARCHIVE
Preventing Type I Diabetes. Here’s How Provention (PRVB) Works.
Here's How Provention's Treatment Works.
Interview With an Actual Provention Bio (PRVB) Clinical Trial Participant.